Plasma Level of Glucagon-like Peptide 1 in Obese Egyptians with Normal and Impaired Glucose Tolerance

Archives of Medical Research

Volumn 45, Issue 1, 2014, Pages 58-62

  Hussein, Magda S ^a   Abushady, Manal M ^a   Refaat, Safa ^b   Ibrahim, Rasha ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b RESEARCH INSTITUTE OF OPHTHALMOLOGY   (Egypt)

Author keywords

Glucose tolerance; Impaired fasting glucose; Obesity; Type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; EGYPT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBID OBESITY; OBESITY; OUTPATIENT DEPARTMENT; WAIST CIRCUMFERENCE;

GLUCOSE TOLERANCE; IMPAIRED FASTING GLUCOSE; OBESITY; TYPE 2 DIABETES;

ADULT; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; OBESITY, MORBID; PREDIABETIC STATE;

EID: 84892555868     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.10.012     Document Type: Article

References (20)

1. De Vegt F., Dekker J.M., Jager A., et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 2001, 285:2109-2113.
2. Santaguida P.L., Balion C., Hunt D., et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. AHRQ Study 2006, 128:1-12.
3. Dakin C.L., Gunn I., Small C.J., et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001, 142:4244-4250.
4. Holst J.J. The physiology of glucagon-like peptide-1. Physiol Rev 2007, 87:1409-1439.
5. Rask E., Olsson T., Soderberg S., et al. Impaired incretin response after a mixed meal is associated with insulin resistance in non-diabetic men. Diabetes Care 2001, 24:1640-1645.
6. Vilsboll T., Krarup J., Sonne S., et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2005, 88:2706-2713.
7. Verdich C., Toubro S., Buemann B., et al. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001, 25:1206-1214.
8. Toft-Nielsen M.B., Madsbad S., Holst J.J. Determinants of the effectiveness of Glucagon-like peptide 1 in type 2 diabetes. J Clin Endocrinol Metab 2001, 86:3853-3860.
9. Lee S., Yabe D., Nohtomi K., et al. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J 2010, 7:119-126.
10. Nauck A.M., Vardarli I., Deacon F.C., et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. Diabetologia 2011, 54:10-18.
11. World Health Organization: Obesity: preventing and managing the global epidemic. Report of a WHO consultation. Geneva;2004.
12. American Diabetes Association: Diagnosis and classification of Diabetes mellitus. Diabetes Care 2006, 29:543-548.
13. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969, 6:24-27.
14. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
15. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complication. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998, 15:539-553.
16. Porstmann T., Kiessig S.T. Enzyme immunoassay techniques, an overview. J Immunol Methods 1992, 150:5-21.
17. Muscelli E., Mari A., Casolaro A., et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008, 57:1340-1348.
18. Vollmer K., Holst J.J., Baller B., et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008, 57:678-687.
19. Fang Z., Xialian T., Hongyi C., et al. Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Int J Med Sci 2012, 9:574-581.
20. Velasquez-Mieyer P.A., Umpierrez G.E., Lustig R.H., et al. Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults. Int J Obes Relat Metab Disord 2004, 28:330-333.